Figure 5.
Figure 5. MP dose reduction and antileukemic efficacy in Nudt15−/− mice. Nudt15−/− mice were used to derive murine leukemia (Arf−/−, BCR-ABL1, GFP) with Nudt15 deficiency. Leukemia-bearing mice (with concordant Nudt15 genotype between host and leukemia) received IP MP therapy (20 or 1 mg/kg per day; red or green, respectively) or vehicle (blue). Leukemia progression was monitored by quantifying the percentage of GFP+ cells (leukemia blast) in peripheral blood. In panel A, each line represents the mean blast percentage, and the shade of the same color indicates standard deviation within the respective group. In panel B, vertical ticks indicate death resulting from toxicity.

MP dose reduction and antileukemic efficacy in Nudt15−/−mice.Nudt15−/− mice were used to derive murine leukemia (Arf−/−, BCR-ABL1, GFP) with Nudt15 deficiency. Leukemia-bearing mice (with concordant Nudt15 genotype between host and leukemia) received IP MP therapy (20 or 1 mg/kg per day; red or green, respectively) or vehicle (blue). Leukemia progression was monitored by quantifying the percentage of GFP+ cells (leukemia blast) in peripheral blood. In panel A, each line represents the mean blast percentage, and the shade of the same color indicates standard deviation within the respective group. In panel B, vertical ticks indicate death resulting from toxicity.

Close Modal

or Create an Account

Close Modal
Close Modal